Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Shanahan KarinOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,306Price:--
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Shanahan KarinOwnership Type:Direct OwnershipSecurities:Common Stock, $0.10 par valueNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,196Price:$52.99
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Shanahan KarinOwnership Type:Direct OwnershipSecurities:Common Stock, $0.10 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,306Price:--
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Yale Phyllis ROwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:645Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Storch Gerald LOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:691Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Samuels Theodore R. IIOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:922Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Rice Derica WOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:691Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Bhatt DeepakOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:161Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Arduini Peter JOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:645Price:$54.23
-
Mar 10, 2024 (filed on Mar 12, 2024)Insider Name:Leung SandraOwnership Type:Direct OwnershipSecurities:Common Stock, $0.10 par valueNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-11,695Price:$53.79
Filings by filing date
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Shanahan KarinOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-3,306Price:--
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Shanahan KarinOwnership Type:Direct OwnershipSecurities:Common Stock, $0.10 par valueNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,196Price:$52.99
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Shanahan KarinOwnership Type:Direct OwnershipSecurities:Common Stock, $0.10 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:3,306Price:--
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Yale Phyllis ROwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:645Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Storch Gerald LOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:691Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Samuels Theodore R. IIOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:922Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Rice Derica WOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:691Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Bhatt DeepakOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:161Price:$54.23
-
Mar 31, 2024 (filed on Apr 02, 2024)Insider Name:Arduini Peter JOwnership Type:Direct OwnershipSecurities:Deferred Share UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:645Price:$54.23
-
Mar 10, 2024 (filed on Mar 12, 2024)Insider Name:Leung SandraOwnership Type:Direct OwnershipSecurities:Common Stock, $0.10 par valueNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-11,695Price:$53.79
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Route 206 And Province Line Road PRINCETON NJ 08543 |
Tel: | N/A |
Website: | https://www.bms.com |
IR: | See website |
Key People | ||
Christopher S. Boerner Chairman of the Board, Chief Executive Officer, Chief Operating Officer | Robert Plenge Executive Vice President, Chief Research Officer, Head of Research, Member of the Leadership Team | David V. Elkins Executive Vice President, Chief Financial Officer, Member of the Leadership Team |
Lynelle Hoch President, Cell Therapy Organization, Member of the Leadership Team | Amanda Poole Chief Human Resource Officer, Executive Vice President, Member of the Leadership Team | Greg Meyers Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team |
Sandra Leung Executive Vice President, General Counsel, Member of the Leadership Team | Cari Gallman Executive Vice President, Corporate Affairs, Member of the Leadership Team | Samit Hirawat Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team | Adam Lenkowsky Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team |
Business Overview |
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib. |
Financial Overview |
For the fiscal year ended 31 December 2023, Bristol-Myers Squibb Co revenues decreased 2% to $45.01B. Net income increased 27% to $8.03B. Revenues reflect Prioritized Brands-Revlimid segment decrease of 39% to $6.1B, Prioritized Brands-Sprycel segment decrease of 11% to $1.93B, United States segment decrease of 1% to $31.56B, other segment decrease of 16% to $699M. |
Employees: | 34,100 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $126,519M as of Dec 31, 2023 |
Annual revenue (TTM): | $45,006M as of Dec 31, 2023 |
EBITDA (TTM): | $20,625M as of Dec 31, 2023 |
Net annual income (TTM): | $8,025M as of Dec 31, 2023 |
Free cash flow (TTM): | $7,907M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $27,492M as of Dec 31, 2023 |
Shares outstanding: | 2,026,758,715 as of Mar 14, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |